Insider Selling: Cerus Co. (NASDAQ:CERS) CFO Sells 23,147 Shares of Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 23,147 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $33,563.15. Following the completion of the sale, the chief financial officer now owns 912,607 shares of the company’s stock, valued at $1,323,280.15. This trade represents a 2.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 7th, Kevin Dennis Green sold 31,148 shares of Cerus stock. The shares were sold at an average price of $1.50, for a total transaction of $46,722.00.
• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The shares were sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Stock Performance

Shares of CERS opened at $1.53 on Thursday. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. The stock has a market cap of $284.26 million, a P/E ratio of -13.91 and a beta of 1.56. The company has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.75. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.54.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. As a group, research analysts predict that Cerus Co. will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Hedge Funds Weigh In On Cerus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new position in Cerus during the fourth quarter worth about $25,000. Rockport Wealth LLC purchased a new stake in shares of Cerus during the fourth quarter worth about $25,000. Cibc World Markets Corp purchased a new stake in shares of Cerus during the fourth quarter worth about $26,000. R Squared Ltd purchased a new stake in shares of Cerus during the fourth quarter worth about $29,000. Finally, Virtu Financial LLC purchased a new stake in shares of Cerus during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.